Tirzepatide vs AOD-9604

Tirzepatide and AOD-9604 are research peptides with distinct mechanisms and evidence bases. Tirzepatide, a 39-amino-acid peptide with a C20 fatty di-acid moiety for once-weekly dosing, is a dual GIP and GLP-1 receptor agonist developed by Eli Lilly. It has received FDA approval for type 2 diabetes (Mounjaro) and chronic weight management (Zepbound), including for severe obstructive sleep apnea in adults with obesity. AOD-9604, a modified fragment of human growth hormone (Tyr-hGH(177-191)) developed at Monash University, retains lipolytic properties without growth-promoting or diabetogenic effects. It underwent six randomized, double-blind, placebo-controlled human trials for obesity in the early 2000s, showing modest fat loss with a placebo-level side effect profile. The FDA granted it GRAS status for food use in 2014, though clinical development for obesity was discontinued. This comparison examines their mechanisms, evidence strength, and research applications.

Tirzepatide is a first-in-class dual agonist of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual activation enhances insulin secretion, suppresses glucagon, delays gastric emptying, and promotes satiety through central and peripheral pathways. Clinical trials consistently demonstrate superior weight reduction among incretin-based therapies, with up to 22.5% mean body weight loss at 72 weeks in the SURMOUNT-1 trial. Research also indicates improvements in glycemic control, with HbA1c reductions exceeding 2% in type 2 diabetes studies. Additionally, exploratory analyses suggest potential benefits for liver fat reduction and non-alcoholic steatohepatitis (NASH), though these require further validation. The C20 fatty di-acid moiety enables albumin binding, supporting once-weekly subcutaneous dosing. Compared to semaglutide, tirzepatide shows greater efficacy in weight loss and glycemic endpoints, likely due to complementary GIP receptor activation.

AOD-9604 is a synthetic peptide corresponding to amino acids 177-191 of human growth hormone, with an N-terminal tyrosine addition (Tyr-hGH(177-191)). It selectively activates lipolysis by binding to a specific receptor on adipocytes, promoting fat breakdown without affecting growth hormone receptors. This mechanism avoids the diabetogenic and mitogenic effects of full-length HGH, as evidenced by no changes in blood glucose, insulin, or IGF-1 levels in clinical studies. Six randomized, double-blind, placebo-controlled human trials in the early 2000s reported modest but consistent fat loss, approximately 5% body weight over 12 weeks, with a side effect profile indistinguishable from placebo. The FDA granted GRAS status for food use in 2014, indicating safety for consumption, but clinical development for obesity was discontinued, limiting large-scale efficacy data. Preclinical models also suggest potential for cartilage repair, though human evidence remains sparse.

Tirzepatide and AOD-9604 target overlapping but distinct research areas within metabolic health. Tirzepatide is primarily studied for weight management and metabolic health, including glycemic control, insulin sensitivity, and cardiovascular outcomes. Its dual incretin mechanism also positions it for research in non-alcoholic fatty liver disease (NAFLD) and NASH. AOD-9604 focuses specifically on fat loss through lipolysis, with no direct effects on glucose metabolism or appetite. It is also investigated for cartilage repair in preclinical models, though human data are limited. Researchers may choose tirzepatide for comprehensive metabolic syndrome models or AOD-9604 for isolated fat metabolism studies without confounding effects on growth or glycemic pathways.

Tirzepatide: Common adverse events (≥5% in clinical trials) include gastrointestinal effects such as nausea, vomiting, diarrhea, constipation, dyspepsia, and abdominal pain. Other reported events include burping, fatigue, GERD, hair loss, hypersensitivity reactions, and injection site reactions. Serious but rare risks include pancreatitis, gallbladder events (e.g., cholecystitis), and dehydration-induced kidney injury. The FDA includes a boxed warning for thyroid C-cell tumors based on rodent studies; researchers should monitor for neck lumps, swallowing difficulty, hoarseness, or shortness of breath. AOD-9604: In extensive human trials, the side effect profile was virtually indistinguishable from placebo. Mild injection site reactions (redness, pain, small welts) are the most common complaint. Mild headaches or flushing are reported in a small percentage of users. No significant effects on blood glucose, IGF-1, or growth-related markers have been observed, supporting its safety in metabolic research.